Basics Fate Therapeutics, Inc. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. IPO Date: October 1, 2013 Sector: Healthcare Industry: Biotech Market Cap: $177.61M Activated in VL: True Average Daily Range Avg Daily Range: $0.57 | 3.54% Avg Daily Range (30 D): $0.05 | 4.08% Avg Daily Range (90 D): $0.04 | 3.79% Institutional Daily Volume Avg Daily Volume: .88M Avg Daily Volume (30 D): 2.26M Avg Daily Volume (90 D): 1.66M Trade Size Avg Trade Size (Sh.): 112 Avg Trade Size (Sh.) (30 D): 316 Avg Trade Size (Sh.) (90 D): 312 Institutional Trades Total Inst.Trades: 3,462 Avg Inst. Trade: $2.74M Avg Inst. Trade (30 D): $.68M Avg Inst. Trade (90 D): $.75M Avg Inst. Trade Volume: .14M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $3.8M Avg Closing Trade (30 D): $1.27M Avg Closing Trade (90 D): $.9M Avg Closing Volume: 204.27K     News May 28, 2025 @ 9:54 PM Fate Therapeutics Announces Phase 1 Data Presentat... Source: N/A Apr 2, 2025 @ 8:01 PM Fate Therapeutics Reports New Employee Inducement ... Source: N/A Feb 28, 2025 @ 6:00 PM NK Cell Therapy Market on Track for Exponential Gr... Source: Delveinsight Nov 29, 2024 @ 6:05 PM Fate Therapeutics Announces Leadership Transition Source: N/A Nov 9, 2024 @ 6:30 PM Fate Therapeutics Highlights Cancer-selective, HER... Source: N/A Financials   TTM Q2 2025 Q1 2025 Basic EPS $-1.46 $-.29 $-.32 Diluted EPS $-1.46 $-.29 $-.32 Revenue $ 8.47M $ 1.91M $ 1.63M Gross Profit $ $ $ Net Income / Loss $ -171.52M $ -34.07M $ -37.62M Operating Income / Loss $ -192.37M $ -36.97M $ -41.28M Cost of Revenue $ $ $ Net Cash Flow $ -.62M $ 5.19M $ M PE Ratio